2024-03-28T20:58:36Z
http://repoint.unil.ch/oaiprovider/
oai:serval.unil.ch:BIB_1562B775FCBE
2024-03-23T01:53:41Z
serval:BIB_1562B775FCBE
First-line nivolumab plus ipilimumab in unresectable malignant pleural mesothelioma (CheckMate 743): a multicentre, randomised, open-label, phase 3 trial.
10.1016/S0140-6736(20)32714-8
000614227700025
33485464
Baas
P.
author
Scherpereel
A.
author
Nowak
A.K.
author
Fujimoto
N.
author
Peters
S.
author
Tsao
A.S.
author
Mansfield
A.S.
author
Popat
S.
author
Jahan
T.
author
Antonia
S.
author
Oulkhouir
Y.
author
Bautista
Y.
author
Cornelissen
R.
author
Greillier
L.
author
Grossi
F.
author
Kowalski
D.
author
Rodríguez-Cid
J.
author
Aanur
P.
author
Oukessou
A.
author
Baudelet
C.
author
Zalcman
G.
author
article
review
2021-01-30
Lancet
1474-547X
0140-6736
journal
397
10272
375-386
Aged
Antineoplastic Agents, Immunological/administration & dosage
Carcinoma, Non-Small-Cell Lung/drug therapy
Drug Therapy
Female
Humans
Ipilimumab/administration & dosage
Male
Mesothelioma, Malignant/drug therapy
Nivolumab/administration & dosage
eng
60_published
peer-reviewed
Publication types: Clinical Trial, Phase III ; Journal Article ; Multicenter Study ; Randomized Controlled Trial ; Research Support, Non-U.S. Gov't
Publication Status: ppublish